119018-29-0
119018-29-0
Chemical Structure
Glimepiride sulfonamide
- CAS No.: 119018-29-0
- Formula:C16H21N3O4S
- Molecular Weight:351.43
IUPAC Name: 3-ethyl-4-methyl-2-oxo-N-(4-sulfamoylphenethyl)-2,5-dihydro-1H-pyrrole-1-carboxamide
InChIKey: AJEMFZRCUKJSES-UHFFFAOYSA-N
SMILES: O=S(C1=CC=C(CCNC(N2C(C(CC)=C(C)C2)=O)=O)C=C1)(N)=O
Biological Activity: Glimepiride sulfonamide acts as both a DPP-IV inhibitor and an α-Amylase inhibitor. It serves as an intermediate for the synthesis of Glimepiride (HY-B0104). Glimepiride sulfonamide stimulates the production and secretion of insulin. It possesses anti-diabetic potential and can be used in diabetes-related research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Glimepiride sulfonamide | 98.0% | Glimepiride sulfonamide acts as both a DPP-IV inhibitor and an α-Amylase inhibitor. It serves as an intermediate for the synthesis of Glimepiride (HY-B0104). Glimepiride sulfonamide stimulates the production and secretion of insulin. It possesses anti-diabetic potential and can be used in diabetes-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glimepiride sulfonamide (Standard) | ≥98% | Glimepiride sulfonamide (Standard) is the analytical standard of Glimepiride sulfonamide. This product is intended for research and analytical applications. Glimepiride sulfonamide is a intermediate, and can be used to synthesize Glimepiride (HY-B0104) (antidiabetic agent). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Parmar HS, et al. Study on gluco-regulatory potential of glimepiride sulfonamide using in silico, in vitro and in vivo approaches. Current pharmaceutical design. 2014;20(32):5212-7. [Content Brief]
- [2]. Bansal G, et al. LC-UV-PDA and LC-MS studies to characterize degradation products of glimepiride. Journal of pharmaceutical and biomedical analysis. 2008 Nov 04;48(3):788-95.
